Achillion Pharmaceuticals, Inc. · New Haven, CT United States (NASDAQ: ACHN)
| 300 George St. | Phone: 203-624-7000 |
| New Haven, CT | Fax: 203-624-7003 |
| 06511 | |
| United States | 
Map This Company |
Achillion Pharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Achillion Pharmaceuticals is looking for the Achilles heel of infectious disease. The firm is developing treatments for infectious diseases, including antiviral treatments for HIV infection and hepatitis C, as well as antibacterials for fighting drug-resistant hospital-based infections. Lead candidate elvucitabine is in late-stage clinical trials for the treatment of HIV; the drug is designed specifically for patients who have become resistant to existing antiviral drugs. Achillion is also focused on the development of three hepatitis C treatments (one of which it is developing in collaboration with biotech firm
Achillion Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ACHN Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 44 |
Executives
16 executives listed for Achillion Pharmaceuticals, Inc.'s New Haven, CT location.
| Chairman | David Scheer | |
|---|---|---|
| President, CEO, and Director | Michael Kishbauch | |
| SVP and CFO | Mary Kay Fenton |